Intellectual Property Notes

UK Supreme Court hands down judgment in Unwired Planet

Patent and Pharma Update, August 2020

UK's exit from the UPC now final

Where is the balance now? Preliminary injunctions in pharmaceutical patent proceedings in 2020 and beyond

Recent decisions of the Federal Court of Australia have significantly changed the way in which parties to pharmaceutical patent litigation should analyse …

The CJEU’s decision in Santen confirms a restrictive interpretation of ‘product’ under article 1(b) and 3(d) of the SPC Regulation, and rejects the possibility of an SPC based on a Marketing Authorisation for a new use of a previously authorised product

The High Court of England & Wales maintains the status quo for Edwards’ PASCAL Transcatheter Valve Repair System when considering a stay of a final injunction pending appeal

Court of Appeal of England & Wales maintains no interim injunction for Neurim and Flynn against generic Circadin® – damages held to be an adequate remedy

UK Supreme Court in Regeneron v Kymab: technical contribution critical to determining sufficiency

Unsuccessful strike out of a quia timet infringement counterclaim

The rock misses its target in this story of “David and Goliath” – the UK High Court's consideration of interim injunctions in Neurim Pharmaceuticals v Mylan

Pepper trumps Broccoli: EPO finds products produced by essentially biological processes are not patentable

COVID-19: PRESSURE POINTS: Developments at Patent Courts in Europe in light of the health emergency (UK, Germany, France, Italy & the EPO)